Non-alcoholic cirrhosis is permanent scarring of the liver caused by fat buildup and chronic inflammation, not by heavy drinking. It develops when years of excess fat in liver cells triggers repeated injury and healing cycles that eventually replace healthy tissue with stiff scar tissue. This is the most advanced stage of a condition now called metabolic dysfunction-associated steatotic liver disease (MASLD), which replaced the older term “non-alcoholic fatty liver disease” (NAFLD) in 2023.
Around 30% of adults worldwide have some degree of fatty liver disease tied to metabolic factors like obesity, type 2 diabetes, or high triglycerides. Only a fraction progress to cirrhosis, but because the early stages are silent, some people don’t learn about the damage until complications appear.
How Fat in the Liver Becomes Permanent Scarring
The process starts with an accumulation of fat inside liver cells. On its own, that fat may cause little harm. Problems begin when toxic byproducts of that fat, including certain saturated fatty acids, free cholesterol, and compounds called ceramides, start injuring hepatocytes (the liver’s main working cells). Damaged hepatocytes release distress signals that recruit immune cells, especially a type of white blood cell called macrophages, into the liver. This stage of active inflammation and cell death is called metabolic dysfunction-associated steatohepatitis, or MASH (previously known as NASH).
Once inflammation takes hold, it activates stellate cells, specialized cells in the liver that normally sit quietly. When switched on, stellate cells begin producing collagen and other fibrous proteins, essentially laying down scar tissue. The injured hepatocytes, the incoming immune cells, and the activated stellate cells communicate through chemical signals that create a self-reinforcing loop: more inflammation triggers more scarring, which triggers more inflammation. Over years or decades, the accumulating scar tissue stiffens the liver, distorts its internal architecture, and blocks normal blood flow. At that point, the liver has reached cirrhosis.
Who Is Most at Risk
The diagnosis of MASLD requires both fat detected in the liver (by imaging or biopsy) and at least one metabolic risk factor. Those risk factors include a BMI of 25 or higher (23 or higher for people of Asian descent), fasting blood sugar at or above 100 mg/dL, blood pressure at or above 130/85, triglycerides at or above 150 mg/dL, or low HDL cholesterol (below 40 mg/dL for men, below 50 for women). Having type 2 diabetes is one of the strongest predictors of progression to cirrhosis. People who carry excess weight around the waist face higher risk even if their overall BMI isn’t dramatically elevated.
Symptoms by Stage
In the early phase, called compensated cirrhosis, the liver still manages to do its job despite the scarring. Most people feel nothing at all during this stage, or they notice only vague problems: mild fatigue, nausea, loss of appetite, or discomfort in the upper right abdomen. Some develop small spider-like blood vessels visible on the skin, or redness on their palms.
As scarring worsens and the liver can no longer compensate, the condition shifts to decompensated cirrhosis. Symptoms become harder to ignore:
- Jaundice: a yellow tint to the skin and whites of the eyes, along with dark urine and pale stools
- Ascites: fluid buildup in the abdomen that causes visible swelling
- Itchy skin without any visible rash
- Easy bruising and bleeding, because the liver produces fewer clotting proteins
- Unexplained weight loss and muscle wasting
- Small yellow fat deposits on the skin or eyelids
Some people first learn they have cirrhosis only when they arrive at a hospital with one of its complications, like internal bleeding or confusion.
How It Is Diagnosed
Doctors often start with a simple blood-based calculation called the FIB-4 index, which combines age, platelet count, and two liver enzymes into a single score. A FIB-4 score below 1.67 generally rules out advanced scarring. A score of 3.48 or higher strongly suggests cirrhosis. Scores between those two numbers fall into an indeterminate zone (about 22% of patients land here) and need further testing.
The most common next step is a FibroScan, a painless ultrasound-based test that measures liver stiffness in kilopascals (kPa). Healthy liver tissue is soft, typically under 7 kPa. A reading of 12.5 kPa or above suggests severe fibrosis, and a reading at or above 17.6 kPa has a 90% positive predictive value for cirrhosis. In people with confirmed cirrhosis, readings often range from the mid-teens all the way up to 75 kPa.
Liver biopsy remains the most definitive test, but it’s invasive and typically reserved for cases where imaging and blood work leave uncertainty, or when doctors need to assess how much active inflammation is present alongside the scarring.
Complications That Can Develop
The scarring in cirrhosis blocks the normal flow of blood through the liver, creating a backup of pressure in the portal vein. This condition, portal hypertension, is the root cause of most serious complications.
Ascites, the accumulation of fluid in the abdominal cavity, is the most common complication of cirrhosis overall. It happens when high portal pressure forces fluid out of blood vessels and into the surrounding space. Mild ascites may only be detectable on an ultrasound; severe cases can add liters of fluid that make it difficult to breathe or eat.
Varices are swollen veins that develop in the esophagus or stomach as blood reroutes around the blocked liver. Up to 50% of people with cirrhosis develop them. These veins are fragile and can rupture, causing sudden, life-threatening bleeding.
Hepatic encephalopathy is a buildup of toxins (primarily ammonia) that the damaged liver can no longer filter. It causes a spectrum of neurological changes, from subtle difficulty concentrating and sleep disruption to visible confusion, slurred speech, and in severe cases, coma. It is often reversible with treatment.
People with cirrhosis also face an elevated risk of liver cancer (hepatocellular carcinoma), which is why routine screening with imaging every six months is standard practice once cirrhosis is diagnosed.
Treatment and Management
There is no medication that reverses established cirrhosis, but slowing further damage and managing complications can significantly extend life. The foundation is addressing the metabolic drivers: losing 7 to 10% of body weight can reduce liver inflammation and, in earlier stages of fibrosis, even partially reverse scarring. Regular physical activity improves insulin sensitivity independently of weight loss.
In March 2024, the FDA approved the first medication specifically targeting the inflammatory stage that precedes cirrhosis. Called Rezdiffra (resmetirom), it is approved for adults with MASH who have moderate to advanced fibrosis but have not yet reached cirrhosis. It is taken as a daily pill alongside diet and exercise. Importantly, this drug is not approved for people who already have cirrhosis, so catching liver disease before that stage matters.
Nutritional support plays a larger role than many people expect. People with cirrhosis are recommended to eat 1.2 to 1.5 grams of protein per kilogram of body weight daily, roughly 1.5 times more than the standard recommendation for healthy adults. This higher intake helps counteract the muscle wasting that cirrhosis commonly causes. Eating a late-evening snack that includes protein can help prevent overnight fasting from accelerating muscle breakdown.
For complications like ascites, treatment typically involves a low-sodium diet and medications that help the body shed excess fluid. Hepatic encephalopathy is managed with agents that reduce ammonia absorption in the gut. Varices may require preventive medications to lower portal pressure, or procedures to band the swollen veins before they bleed.
Prognosis and Liver Transplant
The outlook depends heavily on whether cirrhosis is compensated or decompensated. People with compensated cirrhosis can live for many years, particularly if they address the underlying metabolic issues and avoid further liver insults like alcohol or hepatotoxic medications. Once decompensation occurs, the timeline shortens considerably, and liver transplant evaluation becomes a serious conversation.
For those who do receive a transplant, outcomes are encouraging. Five-year survival after liver transplant for MASH-related cirrhosis is approximately 85%, which is comparable to transplant survival for alcohol-related cirrhosis (80%) and other common causes. The challenge is organ availability: wait times vary widely by region and disease severity, and candidates must demonstrate that the metabolic conditions driving the disease are being managed, since fatty liver can recur in a transplanted organ if the underlying risk factors remain uncontrolled.